A large, collaborative group led by Julie Andersen at the Buck Institute for Research in Aging, Novato, California, demonstrates that lowering the bioavailability of iron—both systemically and in dopaminergic neurons—protects mice against chemically induced Parkinson's...
The tight barrier between brain and blood vessels guards the brain from harm, but also frustrates scientists trying to deliver therapeutic molecules to the CNS...
Pfizer conceded that results of the first of four Phase 3 trials of intravenous bapineuzumab failed to meet its co-primary endpoints in patients with mild to moderate AD...
A foursome of papers in the February 17 Archives of Neurology continues the shifting debates about three epidemiological questions in Alzheimer’s research...
Thanks to a new imaging technology, researchers discovered that amyloid plaques can literally show up overnight and grow to their full size in just a few days...
Though it’s now widely accepted that amyloid-β oligomers are bad news for dendritic spines, most of the data supporting this contention comes from cell culture or tissue slice experiments...
The development of neurotrophic factors for treatment of Alzheimer disease (AD) and other neurodegenerative disorders has proceeded in fits and starts, in no small part due to...